Indegene Limited

NSE: INDGN · Healthcare

₹609.75-0.59%06 Nov 2026

Ask the data

Instant answers about Indegene Limited — computed from its filings, no language model

Market cap₹14,664 cr

Current price₹609.75

High / Low₹619 / ₹424

P/E35.7

P/B4.37

Book value₹139.6

ROE12.2%

ROCE16.8%

Debt / equity0.00

Dividend yield0.33%

EPS (TTM)₹17.09

Face value₹2

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY24	FY25	FY26
Revenue	2,590	2,839	3,510
EBITDA	505	534	619
Operating margin	19.5%	18.8%	17.6%
Interest	49	22	19
Depreciation	76	80	126
Profit before tax	459	539	525
Tax	122	133	124
Net profit	345	407	401
EPS ₹	15.19	17.15	16.72
Operating cash flow	508	442	651
Capex	11	30	44
Dividend paid	0	0	48
Total assets	2,546	3,326	4,620
Equity	1,429	2,616	3,139

Quarterly performance

last 11 quarters · ₹ crore

showing latest 8 of 11 periods

	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	673	676	687	720	756	761	804	942	1,003	1,063	1,122
Operating profit	139	129	126	132	148	155	141	160	164	174	186
Operating margin	20.6%	19.1%	18.4%	18.3%	19.5%	20.4%	17.5%	16.9%	16.3%	16.4%	16.5%
Other income	23	22	21	38	26	22	20	19	11	29	15
Interest	12	12	4	3	3	4	4	5	7	6	7
Depreciation	18	20	19	20	21	22	23	40	42	44	46
Profit before tax	134	120	124	146	149	152	133	135	105	153	147
Tax	39	32	32	37	32	36	31	32	25	36	35
Net profit	97	88	92	110	118	116	0	103	80	116	112
EPS ₹	4.27	3.79	3.84	4.59	4.91	4.86	4.26	4.29	3.32	4.84	4.67
Revenue YoY	—	—	—	—	12.3%	12.5%	17.1%	30.8%	32.8%	39.7%	39.6%
Profit YoY	—	—	—	—	21.7%	32.7%	-100.0%	-6.2%	-32.2%	-0.2%	—

Returns & margins

trailing-twelve-month, per quarter

	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	16.3%	15.5%	16.6%	12.0%	11.8%	9.5%	9.5%	12.2%
ROCE	23.5%	21.5%	22.4%	20.7%	20.4%	17.3%	17.4%	16.8%
Net margin	14.0%	14.3%	14.9%	11.3%	10.3%	8.5%	7.8%	10.0%
EBITDA margin	19.1%	18.8%	19.2%	18.9%	18.5%	17.6%	16.7%	16.5%
Debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest coverage	17.78	25.51	41.84	43.09	38.45	28.20	24.89	22.51
Asset turnover	0.91	0.85	0.88	0.85	0.91	0.76	0.83	0.88

Balance sheet

equity vs borrowings over time · ₹ crore

	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	44	48	48	48	48	48
Other equity / reserves	1,385	2,312	2,568	2,818	3,091	3,310
Total equity	1,429	2,360	2,616	2,866	3,139	3,358
Borrowings	403	0	0	0	0	0
Current liabilities	611	510	564	550	1,086	1,118
Non-current liabilities	506	154	146	160	395	217
Total assets	2,546	3,024	3,326	3,576	4,620	4,693
Property, plant & equipment	114	111	135	161	194	228
Capital work-in-progress	—	0	4	0	12	0
Investments	796	917	1,290	778	1,100	1,019
Inventories	0	0	0	0	0	0
Receivables	648	705	751	787	982	1,145
Cash & equivalents	189	312	241	368	301	141

Cash flow

annual · ₹ crore · line = free cash flow

	FY24	FY25	FY26
Cash from operations	508	442	651
Cash from investing	-327	-683	-512
Cash from financing	-66	288	-83
Capex	11	30	44
Free cash flow	497	412	606
Dividends paid	0	0	48

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹228 cr5%

Investments

₹1,019 cr22%

Receivables

₹1,145 cr24%

Cash & equivalents

₹141 cr3%

Other assets

₹2,159 cr46%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Indegene Limited	14,664	609.75	35.7	4.37	12.2%

StoxGud checklist: Bullish setup · 8/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+0.4%

6 months+14.7%

1 year+11.8%

3Y CAGR—

5Y CAGR—

10Y CAGR—

50-day avg₹593.95

200-day avg₹524.90

RSI (14)54

FAQs

What is the share price of Indegene Limited?

Indegene Limited (INDGN) closed at ₹609.75 on NSE on 06 Nov 2026.

What is the market cap of Indegene Limited?

₹14,664 crore at the latest close.

What is the P/E ratio of Indegene Limited?

35.7, on trailing-twelve-month earnings from its filings.

How fast is Indegene Limited growing?

Indegene Limited: Latest-quarter revenue is up 39.6% year on year.

How profitable is Indegene Limited?

On a trailing-twelve-month basis return on equity is 12.2%, return on capital employed 16.8%, operating margin 16.5%, net margin 10.0%.

How much debt does Indegene Limited have?

Indegene Limited is debt-free: debt to equity is 0.00 with borrowings of ₹0 cr against cash of ₹141 cr (balance sheet of 2026-09-30). Operating profit covers interest 22.5 times.

Financials parsed from Indegene Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '24, annual from FY24, balance sheet from Mar '24. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.